Search results
Results from the WOW.Com Content Network
On 18 November 2005, the U.S. Food and Drug Administration (FDA) alerted healthcare professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing in some people, and requested that manufacturers update warnings in their existing product labeling.
Umeclidinium bromide is a long-acting muscarinic antagonist. [14] This combination was approved by the FDA on December 18, 2013 [15] for the long-term maintenance treatment of COPD. On March 28, 2014, it was approved in European countries [16] and in Russia [17] under the same trade name.
Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. [7] It is injected just under the skin. [7] Effects generally begin an hour after use. [7]
It was marketed in 1990. Formoterol, another long-acting β 2-agonist, was marketed shortly after. This long duration of action made the treatment for severe asthma and COPD more convenient for the patients because it is inhaled twice a day. [1] In 2013 an extra long-acting β 2-agonist, vilanterol, was marketed. Its duration of action lasts ...
It contains budesonide, a steroid; and formoterol, a long-acting β 2-agonist (LABA). [2] The product monograph does not support its use for sudden worsening or treatment of active bronchospasm. [2] However, a 2020 review of the literature does support such use. [6] It is used by breathing in the medication. [2]
Terbutaline, sold under the brand names Bricanyl and Marex among others, is a β 2 adrenergic receptor agonist, used as a "reliever" inhaler in the management of asthma symptoms and as a tocolytic (anti-contraction medication) to delay preterm labor for up to 48 hours.
Orciprenaline, also known as metaproterenol, is a bronchodilator used in the treatment of asthma. [1] [2] Orciprenaline is a moderately selective β 2 adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on α adrenergic receptors.
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist [5] developed by Novartis. It needs to be taken only once a day, [6] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking).